Post hoc analysis of clinical efficacy end points, overall population. HRs for TTRFD (A), the primary clinical efficacy end point, and key secondary efficacy end points TTD (B), TTDIVO (C), and CIVO (D) in RESET study. HRs with 95% CIs are shown for TTRFD, TTD, and TTDIVO end points for subjects with different duration of time from onset of VOC symptoms to first dose of rivipansel/placebo. The ratio of medians and 95% CIs are shown for CIVO end point for subjects with different duration of time from onset of VOC symptoms to first dose of rivipansel/placebo. HRs with upper CIs <1.0 are considered to be statistically significant. NS, not significant.